teva pharmaceutical-sp adr
Director, Member of Finance & Invesment Committee, Member of Human Resources & Compensation Committee and Member of Corporate Governance & Nominating Committee, Teva Pharmaceutical Industries Limited
|Age||Total Calculated Compensation||This person is connected to 71 board members in 7 different organizations across 8 different industries.|
See Board Relationships
Mr. Roger Abravanel served as a Business Advisor of Clessidra SGR S.p.A. and served there from 2008 to 2011. Mr. Abravanel held many leadership positions in industry practice groups, including the global private equity practice and the specialty chemicals/pharmaceuticals practice. He served as a Senior Advisor at Magenta Investimenti. Prior to that, he served as a Management Consultant at McKinsey & Co. for 30 years, 20 of which as a Senior Partner. At McKinsey & Company, ...
5 Basel StreetPhone: 972 3 926 7267
Petach Tikva, -- 49131
Fax: 972 3 923 4050
Board Members Memberships*
Independent Director and Coordinator of Remuneration & Nominations Committee
Former Independent Director and Member of Human Resources Committee
Director, Member of Finance & Invesment Committee, Member of Human Resources & Compensation Committee and Member of Corporate Governance & Nominating Committee
Former Non-Executive Director and Member of Remuneration Committee
Unknown/Other Education 1968
Politecnico di Milano
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Omar S. Ishrak||Chairman and Chief Executive Officer|
|Miles D. White||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|Robert L. Parkinson Jr.||Chairman, Chief Executive Officer and President|
Baxter International Inc.
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Richard A. Gonzalez||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|$1.6M||Compensation as of Fiscal Year 2014.|